Our Company was originally incorporated as `Molbio Diagnostics Private Limited' at Panaji, as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 20, 2000, issued by the RoC. Thereafter, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the extraordinary general meeting of our Shareholders held on November 22, 2024, and the name of our Company was changed to Molbio Diagnostics Limited, and a fresh certificate of incorporation dated January 16, 2025 was issued to our Company by the RoC.Major Events and Milestones:2000- Incorporation of our Company- Our R&D arm, Bigtec Private Limited, one of our Subsidiaries commenced its operations2005- Bigtec directs its focus to chip-based PCR research2009- Bigtec develops a `lab-on-a-chip' model2011- Entered into a joint venture agreement dated August 1, 2011 with Bigtec Innovations Private Limited and Bigtec Private Limited2013- Launch of the semi-automatic PCR device `Truelab Uno"2015- Amalgamation of Bigtec Innovations Private Limited with our Company2017- Expert Committee on TB Diagnostics recommended the use of the `TrueNat MTB' and `TrueNat MTB-Rif' in the National Tuberculosis Elimination Programme (at the time known as the Revised National Tuberculosis Control Programme)2018- Launch of fully- automatic PCR device `Truelab Uno" and approved by the Indian Council for Medical Research ("ICMR")2019- Received `License to manufacture for sale and distribution of medical device' for chip based real time PCR test for hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India- Received `License to manufacture for sale and distribution of medical device' for chip based real time duplex PCR test for human papillomavirus high risk types 16, 31 and 18, 45 from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India Investment by India Business Excellence Fund III in our Company2020- World Health Organisation endorsed TrueNat as the primary diagnostic test for MTB and MTB-RIF Received `License to manufacture for sale and distribution of medical device' for chip based real time PCR test for beta coronavirus from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India- Received `License to manufacture for sale and distribution of medical device' for chip based real time PCR test for HIV-1 virus from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India2022- Investment by V Sciences Investments Pte. Ltd. in our Company2023- Acquisition of Prognosys Medical Systems Private Limited to venture into radiology equipment- Acquisition of Prognosys Healthcare (India) Private Limited2024- Launched `Edge', a scaleup partnership initiative between our Company and Bigtec- Investment of 19.68% of the paid-up equity share capital of OptraScan, INC to diversify to digital pathology scanners2025- First Indian company to receive the Class C IVDR (EU 2017/746) Technical Documentation Assessment Certificate for Truenatr CT/NG which has been issued by TUV SUD Product Service GmbH- Investment of an additional 40.32% of the paid-up equity share capital of OptraScan INC- Prognosys Medical Systems Private Limited received US FDA 510(k) clearance for PRORAD ATLAS ULTRAPORTABLE AND ULTRAPORTABLE PLUS2026- Prognosys Medical Systems Private Limited received EU Quality Management System certification under EU MDR 2017/745 for its PRORAD range of radiology systems- Truenat HR-HPV Plus meets International Agency for Research on Cancer (IARC) validation criteria in multicentre study- We entered into a collaboration and license agreement with Equine Biotech Private Limited for development of veterinary diagnostic products, including assay design and validation- OptraScan, INC received US FDA 510(k) clearance (K260755) for its OptraSCAN System